Compare ADMA Biologics Inc (ADMA) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs MobilEye Global Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while MobilEye Global Inc trades at $8.97 (market cap $7.54B). The key difference: MobilEye Global Inc is far larger — about 3.4× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | MBLY | |
|---|---|---|
Market Cap | $2.22B | $7.54B |
Sector | Health | Technology |
52-Week High | $20.38 | $15.54 |
52-Week Low | $7.60 | $6.56 |
Enterprise Value | $2.29B | $6.10B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
